A

AIM ImmunoTech Inc
AMEX:AIM

Watchlist Manager
AIM ImmunoTech Inc
AMEX:AIM
Watchlist
Price: 1.19 USD 5.31% Market Closed
Market Cap: 3.4m USD

Net Margin
AIM ImmunoTech Inc

-13 360.3%
Current
-12 890%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-13 360.3%
=
Net Income
-16.2m
/
Revenue
121k

Net Margin Across Competitors

No Stocks Found

AIM ImmunoTech Inc
Glance View

Market Cap
3.4m USD
Industry
Biotechnology

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 21 full-time employees. The firm is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The firm's products are Alferon N Injection and Ampligen. Alferon N Injection is a natural-source, glycosylated, multi-species alpha interferon product. Alferon is used for the treatment of refractory (resistant to other treatment) or recurring external genital warts in patients 18 years of age or older. Ampligen (rintatolimod), which is a drug of macromolecular RNA (ribonucleic acid) molecules, it is a sterile solution indicated for the treatment of severely debilitated patients with Chronic Fatigue Syndrome (CFS) who have been diagnosed for longer than one year. Ampligen is used in combination with checkpoint blockade therapies. Ampligen is also being used as a monotherapy to treat pancreatic cancer patients.

AIM Intrinsic Value
Not Available
A
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-13 360.3%
=
Net Income
-16.2m
/
Revenue
121k
What is the Net Margin of AIM ImmunoTech Inc?

Based on AIM ImmunoTech Inc's most recent financial statements, the company has Net Margin of -13 360.3%.

Back to Top